Related Experiment Video
Updated: Mar 15, 2026

Application of MassSQUIRM for Quantitative Measurements of Lysine Demethylase Activity
Published on: March 11, 2012
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1
Yuichiro Yoshioka1,2, Takehiro Suzuki3, Yo Matsuo4
1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, MC2115 Chicago, IL 60637, USA.
Abstract:
AKT1 is a cytosolic serine/threonine kinase that is overexpressed in various types of cancer and has a central role in human tumorigenesis. Although it is known that AKT1 is post-translationally modified in various ways including phosphorylation and ubiquitination, methylation has not been reported so far. Here we demonstrate that the protein lysine methyltrasnferase SMYD3 methylates lysine 14 in the PH domain of AKT1 both in vitro and in vivo. Lysine 14-substituted AKT1 shows significantly lower levels of phosphorylation at threonine 308 than wild-type AKT1, and knockdown of SMYD3 as well as treatment with a SMYD3 inhibitor significantly attenuates this phosphorylation in cancer cells. Furthermore, substitution of lysine 14 diminishes the plasma membrane accumulation of AKT1, and cancer cells overexpressing lysine 14-substiuted AKT1 shows lower growth rate than those overexpressing wild-type AKT1. These results imply that SMYD3-mediated methylation of AKT1 at lysine 14 is essential for AKT1 activation and that SMYD3-mediated AKT1 methylation appears to be a good target for development of anti-cancer therapy.
Insights
The protein lysine methyltransferase SMYD3 methylates AKT1 at lysine 14, a novel modification essential for AKT1 activation and cancer cell growth. This SMYD3-mediated methylation of AKT1 is a potential therapeutic target for anti-cancer treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- AKT1 is a key serine/threonine kinase implicated in tumorigenesis and frequently overexpressed in cancers.
- Post-translational modifications like phosphorylation and ubiquitination are known for AKT1, but methylation has not been previously reported.
Purpose of the Study:
- To investigate the potential methylation of AKT1.
- To identify the enzyme responsible for AKT1 methylation and elucidate its functional consequences in cancer.
Main Methods:
- In vitro and in vivo methylation assays using protein lysine methyltransferase SMYD3.
- Site-directed mutagenesis to substitute lysine 14 of AKT1.
- Western blotting to assess AKT1 phosphorylation at threonine 308.
- Cellular assays to evaluate plasma membrane accumulation and cancer cell growth rates.
- SMYD3 knockdown and inhibitor treatments in cancer cells.
Main Results:
- SMYD3 was identified as the enzyme that methylates lysine 14 (K14) in the PH domain of AKT1.
- Methylation of AKT1 at K14 significantly reduced phosphorylation at threonine 308 (T308).
- SMYD3 inhibition or knockdown attenuated AKT1 T308 phosphorylation in cancer cells.
- K14 substitution diminished AKT1 plasma membrane localization and reduced cancer cell growth rates.
Conclusions:
- SMYD3-mediated methylation of AKT1 at K14 is a critical regulatory mechanism for AKT1 activation.
- This methylation event is essential for AKT1's role in promoting cancer cell proliferation.
- SMYD3-mediated AKT1 methylation represents a promising therapeutic target for developing novel anti-cancer strategies.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
MAPK Signaling Cascades
Cytoskeletal Linker Proteins - Plakins

